PRMT5 and lymphoma: To determine whether PRMT5 activity is vital to growth and survival of canine lymphoma cells, we treated 17–71, CLBCL-1, and OSW cell lines with the highly selective PRMT5 inhibitor C220 and evaluated cellular viability by Annexin-V/PI staining with flow cytometry (Fig 2A and 2B) and viable cell proliferation by MTS (Fig 2C).